MDS without clonal marker: when depth outperforms breadth

Bernard E, Tuechler H, Greenberg Peter L, Hasserjian Robert P, Arango Ossa Juan E, Nannya Y, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid. 2022;1:EVIDoa2200008.

Article 
PubMed 

Google Scholar 

Cargo C, Bernard E, Beinortas T, Bolton KL, Glover P, Warren H, et al. Predicting cytopenias, progression, and survival in patients with clonal cytopenia of undetermined significance: a prospective cohort study. Lancet Haematol. 2024;11:e51–e61.

Article 
CAS 
PubMed 

Google Scholar 

Huber S, Baer C, Hutter S, Wossidlo N, Hoermann G, Pohlkamp C, et al. Genomic landscape of CCUS compared to MDS and its implications on risk prediction. Leukemia. 2024;38:1634–7.

Article 
PubMed 
PubMed Central 

Google Scholar 

Nazha A, Sekeres MA, Bejar R, Rauh MJ, Othus M, Komrokji RS, et al. Genomic biomarkers to predict resistance to hypomethylating agents in patients with myelodysplastic syndromes using artificial intelligence. JCO Precis Oncol. 2019;3:PO.19.00119.

PubMed 
PubMed Central 

Google Scholar 

Polprasert C, Niparuck P, Rattanathammethee T, Chuncharunee S, Kobbuaklee S, Songserm K, et al. Excellent prognosis of low-risk myelodysplastic syndromes (MDS) without detectable myeloid-related mutations. Clin Lymphoma Myeloma Leuk. 2022;22:e293–e9.

Article 
CAS 
PubMed 

Google Scholar 

Huber S, Haferlach T, Müller H, Meggendorfer M, Hutter S, Hoermann G, et al. MDS subclassification-do we still have to count blasts? Leukemia. 2023;37:942–5.

Article 
PubMed 
PubMed Central 

Google Scholar 

Wang SA, Ok CY, Kim AS, Lucas F, Morgan EA, Thakral B, et al. Myelodysplastic syndromes with no somatic mutations detected by next-generation sequencing display similar features to myelodysplastic syndromes with detectable mutations. Am J Hematol. 2021;96:E420–e3.

Article 
CAS 
PubMed 

Google Scholar 

Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36:1703–19.

Article 
PubMed 
PubMed Central 

Google Scholar 

Sondka Z, Bamford S, Cole CG, Ward SA, Dunham I, Forbes SA. The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers. Nat Rev Cancer. 2018;18:696–705.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Lee WH, Lin C-C, Tsai C-H, Tien F-M, Lo MY, Tseng M-H, et al. Clinical characteristics and prognostic implications for myelodysplastic syndromes/neoplasms patients with or without cytogenetic abnormalities or gene mutations. Blood. 2024;144:6752.

Article 

Google Scholar 

Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data. Blood. 2022;140:1200–28.

Greenberg PL, Stone RM, Abaza Y, Al-Kali A, Anand S, Ball B, et al. NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025. J Natl Compr Canc Netw. 2025;23:66–75.

Article 
CAS 
PubMed 

Google Scholar 

Meggendorfer M, Walter W, Nadarajah N, Haferlach C, Kern W, Haferlach T. Cracking a nut with a sledgehammer? – Broadening the spectrum of gene mutation analysis in MDS does not add clinically relevant information. Blood. 2020;136:30.

Article 

Google Scholar